Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Clinical study

Upadacitinib increases risk of herpes zoster and NMSC

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Treatment with upadacitinib in patients with rheumatoid arthritis (RA) does not increase the risk of major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) versus comparators, but increases the risk of herpes zoster (HZ) and NMSC, according to findings of an AbbVie-funded pooled analysis of data from phase III trials published in the Annals of the Rheumatic Diseases . …
Literatur
Zurück zum Zitat Fleischmann R, et al. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Annals of the Rheumatic Diseases : 12 Jun 2023. Available from: URL: http://doi.org/10.1136/ard-2023-223916 Fleischmann R, et al. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Annals of the Rheumatic Diseases : 12 Jun 2023. Available from: URL: http://​doi.​org/​10.​1136/​ard-2023-223916
Metadaten
Titel
Upadacitinib increases risk of herpes zoster and NMSC
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41682-z

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Fingolimod

Case report

Rifabutin

Case report

Hydroxycarbamide

Case report

Dimeticone